Skip to main content
MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. logo

MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 688062 ISIN · CNE100005RD2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 541 across all filing types
Latest filing 2024-05-23 Proxy Solicitation & In…
Country CN China
Listing Shanghai Stock Exchange 688062

About MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.

https://www.mabwell.com/en/

Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of therapeutic antibodies and innovative biologics. The company maintains an integrated R&D and manufacturing platform covering the full drug lifecycle, from target discovery and preclinical research to clinical development and commercial production. Its therapeutic pipeline addresses critical needs in oncology, autoimmune diseases, metabolic disorders, ophthalmology, and infectious diseases. Mabwell leverages proprietary technology platforms, including antibody-drug conjugates (ADCs), bispecific antibodies, and high-throughput screening, to develop a diverse portfolio of novel drug candidates and biosimilars. The organization is committed to delivering high-quality, accessible therapeutic solutions through its end-to-end biotechnological capabilities.

Recent filings

Filing Released Lang Actions
迈威生物关于召开2024年第二次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2024 second extraordinary general meeting of shareholders, detailing the meeting date, voting methods, agenda items, and procedural instructions. It includes information about shareholder registration, proxy authorization, and voting procedures. There is no financial data, earnings, or report content. The document is an announcement related to a shareholder meeting rather than the meeting materials or results themselves. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since it is a notice of the meeting and voting procedures rather than solicitation materials or voting results, it is best classified as a Proxy Solicitation & Information Statement (PSI). The document length is under 5,000 characters and it is a formal meeting notice with agenda and voting instructions, typical of PSI filings.
2024-05-23 Chinese
迈威生物2024年第二次临时股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as materials for the "2024 Second Extraordinary General Meeting of Shareholders" of Maiwei (Shanghai) Biotechnology Co., Ltd. It contains detailed meeting notices, agenda, proposals for shareholder voting, including corporate governance matters such as appointment of an independent director and guarantee provision changes. The content is focused on the meeting procedures, proposals to be voted on, and related corporate governance information. It is not a full annual or interim financial report, nor an earnings release or audit report. It is not a transcript or presentation. It is a detailed meeting material document for a shareholders' meeting, which fits the definition of AGM Information (AGM-R). The document length (7321 characters) and detailed agenda and proposals confirm it is the meeting materials themselves, not just an announcement of a meeting or voting results. Therefore, the classification is AGM Information (AGM-R).
2024-05-23 Chinese
迈威生物独立董事候选人声明与承诺（秦正余）
Board/Management Information Classification · 95% confidence The document is a declaration and commitment statement by an independent director candidate of a company, detailing qualifications, compliance with regulatory requirements, and independence criteria. It is not a financial report, earnings release, or any form of meeting material. It does not announce changes in management but is a formal statement related to governance and director qualifications. This fits best under Board/Management Information (MANG) as it relates to board member candidacy and qualifications.
2024-05-23 Chinese
迈威生物自愿披露关于9MW2821在2024年美国临床肿瘤学会（ASCO）年会以口头报告形式报告临床数据及最新进展的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by Maiwei Biotech about clinical data and latest progress of their drug 9MW2821 presented as an oral report at the 2024 ASCO annual meeting. It contains detailed clinical trial results, safety data, and risk warnings. The document is relatively short (3130 characters) and is an announcement of clinical data presentation rather than a full clinical study report or financial report. It does not contain financial statements or detailed financial analysis. It is not an earnings release or annual/interim report. It is primarily a regulatory announcement about clinical progress and risk disclosure. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-05-23 Chinese
迈威生物第二届监事会第十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a supervisory board meeting resolution by a company, detailing the meeting's convening, attendance, and the approval of a specific proposal regarding guarantees for subsidiaries. It includes voting results and mentions that the proposal will be submitted to the shareholders' meeting for further approval. The document does not contain financial statements, audit results, or detailed financial data. It is not a full report but an announcement of a board/management decision. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on management decisions, not a report or regulatory filing.
2024-05-23 Chinese
迈威生物关于独立董事辞职暨提名独立董事并调整第二届董事会专门委员会委员的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of an independent director and the nomination of a new independent director, along with adjustments to the board's specialized committees. It discusses board member changes, qualifications, and compliance with regulatory requirements. There is no financial data, earnings information, or report publication mentioned. The content clearly relates to changes in the company's board of directors and senior management. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and focused on management changes, not a full report or announcement of a report publication.
2024-05-23 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.